Cost-effectiveness of add-on lamotrigine therapy in clinical practice

Add-on therapy of lamotrigine for patients with uncontrolled epilepsy offers improved health outcomes. Lamotrigine therapy is associated with increased cost (€453) and an annual incremental cost-effectiveness ratio of €954. These data, together with utility data published in the literature, support the notion that lamotrigine should be considered as an add-on therapy in for patients with refractory epilepsy.